Health

Precision cancer care brings clinical gains to 93% of hospitals

Precision cancer care brings clinical gains to 93% of hospitals RUSSPAIN.com © russpain.com
Precision cancer care brings clinical gains to 93% of hospitals © russpain.com
A national report says 93% of hospitals see significant clinical benefits from precision oncology. Access to next-generation sequencing has reached 87% of centres, but staff shortages and uneven resources remain major barriers.

More than half of hospitals with molecular tumour boards cannot say how often their recommendations lead to a change in treatment. That leaves a gap in measuring precision oncology’s impact, even as hospitals report clinical benefits from its use.

The second edition of Implantación y regulación de la Oncología de Precisión en España. Informe 2026, presented by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP-IAP), found that 56% of hospitals with these boards do not know what proportion of their recommendations changes treatment. The report draws on responses from 116 hospitals across 17 autonomous communities, including Ceuta, as well as eight regional administrations.

Against that measurement gap, 93% of hospitals said precision oncology provides significant clinical improvements for patients. Some 78% reported benefits for survival and quality of life. Hospitals also said the approach helps them select targeted treatments and include patients in clinical trials, while reducing uncertainty in rare cancers. SEOM describes the clinical rationale for this approach as identifying molecular alterations linked to tumour growth and proliferation, which can guide the use of targeted therapies.

Access to next-generation sequencing (NGS) stands at 87%, while 84% of hospitals said they had fully implemented the common National Health System (SNS) catalogue of genetic and genomic tests, which covers 57 biomarkers. A further 76% have a specific precision-medicine strategy or are developing one. The study was prepared by the SEOM Observatory for Precision Oncology in collaboration with SEAP-IAP. In a SEOM publication on lung-cancer precision medicine, dated 16 November 2026 and updated on 17 November, the society said NGS is enabling the identification of a growing number of molecular alterations with potential therapeutic relevance. It also emphasizes that testing decisions should reflect the patient’s clinical context, with tumour histology and disease stage also taken into account.

That national picture masks differences between centres. Among hospitals with 200 to 500 beds, full implementation of the biomarker catalogue rose from 67.7% in 2025 to 82% in 2026. The share with a dedicated strategy increased from 35.5% to 42%. Yet only 22% of medium-sized hospitals carry out sequencing in their own facilities; they more often rely on external laboratories or reference centres.

Workforce capacity is a broader constraint. Nine in ten hospitals consider their staffing inadequate, rising to all hospitals with more than 1,000 beds. A separate labour-market report recorded rising unemployment in Spain's third quarter, though the oncology study does not link the two findings. In the hospital survey, 82% cited a shortage of professionals and 73% pointed to financial limits. Technical staff were the most commonly requested addition, identified by 92% of hospitals; 87% sought more pathologists and molecular biologists.

Uneven capacity also affects quality controls. External quality-control programmes involve 77% of participating centres, but only 27% hold ISO 15189 accreditation. The figure is 44% among hospitals with more than 1,000 beds and 16% among medium-sized centres. Liquid biopsy is available in some form at 77% of hospitals, yet only 8% use it routinely. SEOM describes liquid biopsy as a complement to tissue analysis: circulating tumour DNA in blood can reveal certain molecular alterations, while tissue testing remains an important part of assessment.

SEOM and SEAP-IAP recommend narrowing differences between hospitals and regions while strengthening staffing. They also call for better diagnostic quality, faster response times and shared indicators to assess clinical impact. Although 78% of hospitals record biomarker-based treatment decisions in patients’ medical records, the report says this does not always show whether molecular-board recommendations were followed.

Richard Reid RUSSPAIN.com
Editor

Richard Reid

Richard Reid is the News Editor at RUSSPAIN.COM. He oversees editorial standards, source review and corrections and writes across general news, including politics, economics and social affairs.